MedWatch

Össur key market sales normalize during second quarter

Prosthetics manufacturer Össur has experienced significant improvements to its growth in Q2 2021, compared to the same period last year which was hugely affected by covid-19.

Photo: Össur / PR

Icelandic prosthetics firm Össur's key market sales have normalized during the second quarter of this year, with large growth achieved compared to the same period in 2020.

"Sales continued to normalize on our key markets, both within Prosthetics and Bracing & Supports. The sales growth during the second quarter was high, as the comparable period in 2020 was highly affected by covid-19," says Jon Sigurdsson, CEO of Össur, in the company's quarterly report.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs